SEHK:6181
SEHK:6181Luxury

3 Asian Growth Companies Insiders Own With Up To 37% Earnings Growth

As global markets navigate a complex landscape marked by fluctuating consumer sentiment and evolving trade dynamics, Asian markets continue to capture investor interest with their growth potential and strategic positioning. In this environment, companies exhibiting strong insider ownership can be particularly appealing, as such ownership often signals confidence in the company's future prospects and alignment with shareholder interests.
SEHK:1318
SEHK:1318Personal Products

Asian Stocks Estimated To Be Up To 38.1% Below Intrinsic Value

As global markets face challenges such as AI valuation concerns and economic uncertainties, Asian stocks have shown resilience with some indices reaching new highs. In this environment, identifying undervalued stocks becomes crucial, as they may offer potential opportunities for investors seeking to capitalize on discrepancies between market price and intrinsic value.
SEHK:340
SEHK:340Metals and Mining

Asian Penny Stocks To Watch In November 2025

Amid the evolving global economic landscape, Asian markets have shown resilience, with Chinese indices experiencing gains due to easing trade tensions. In this context, penny stocks—often smaller or newer companies—remain a noteworthy investment area despite their historical connotations. These stocks can offer a unique blend of affordability and growth potential when backed by strong financials, making them intriguing options for investors seeking opportunities beyond mainstream equities.
SEHK:1109
SEHK:1109Real Estate

How Investors May Respond To China Resources Land (SEHK:1109) After Hong Kong’s Economic Rally and Trade Truce

In recent days, Hong Kong’s economy has shown resilience with 3.8% GDP growth and rising retail sales, providing support to key developers like China Resources Land. A recent U.S.-China trade truce and tariff reductions offer further relief to companies involved in cross-border property markets, even as China faces manufacturing headwinds. To assess what this means for China Resources Land, we’ll explore how Hong Kong’s strong economic performance influences the company’s investment...
SEHK:388
SEHK:388Capital Markets

Hong Kong Exchanges and Clearing (SEHK:388): Assessing Valuation After Strong Earnings Growth

Hong Kong Exchanges and Clearing (SEHK:388) just released its latest earnings, showing a clear jump in both revenue and net income for the third quarter and the year to date, compared to last year. See our latest analysis for Hong Kong Exchanges and Clearing. Strong results have helped drive Hong Kong Exchanges and Clearing’s share price up by more than 50% year-to-date. Its total shareholder return over the past year reached an impressive 37%. That momentum reflects renewed optimism...
SEHK:1199
SEHK:1199Infrastructure

COSCO SHIPPING Ports (SEHK:1199): Valuation Insights Following Strong Nine-Month Earnings Growth

COSCO SHIPPING Ports (SEHK:1199) released its third quarter and nine-month earnings, drawing attention for showing higher sales and net income compared to last year. Investors are likely watching to see how these stronger results play out. See our latest analysis for COSCO SHIPPING Ports. The recent bump in nine-month earnings has come as COSCO SHIPPING Ports' share price has gained steady ground, up 29.3% year-to-date and closing at $5.91. With a 43.6% total return for the year, the stock's...
SEHK:9995
SEHK:9995Biotechs

RemeGen (SEHK:9995) Valuation in Focus After Sales Growth and Positive Telitacicept Trial Results

RemeGen (SEHK:9995) just posted stronger sales numbers and trimmed its net loss for the first nine months of 2025. At the same time, new study results for its telitacicept drug are bolstering investor confidence. See our latest analysis for RemeGen. RemeGen’s stock has been volatile but delivered impressive gains for investors this year, with the share price up 524% year-to-date and a one-year total shareholder return of nearly 340%. After spiking sharply on optimism about its clinical...
SEHK:9966
SEHK:9966Biotechs

Can Alphamab Oncology’s (SEHK:9966) FDA Fast Track Milestone Reshape Its Competitive Position in Oncology?

Alphamab Oncology recently announced that its drug candidate JSKN003 has received Fast Track Designation from the U.S. FDA for the treatment of platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer, without restriction by HER2 expression. This regulatory milestone builds on promising international clinical trial data and highlights momentum in Alphamab's pipeline of antibody-based oncology therapies. We'll explore how the U.S. FDA's Fast...